Navigation Links
Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission

t. The primary endpoint of the study is objective response rate (complete and partial response). Secondary endpoints include duration of response, progression-free survival and overall survival. In August 2006, the Company announced that it reached agreement with the FDA under the Special Protocol Assessment process on the design of this pivotal Phase 2 trial. The Company currently anticipates that patient enrollment at approximately 35 centers in the U.S., Canada and Europe will be completed by the third quarter of 2008.

About PDX (pralatrexate)

PDX is a novel, small molecule chemotherapeutic agent that inhibits dihydrofolate reductase, or DHFR, a folic acid (folate)-dependent enzyme involved in the building of nucleic acid, or DNA, and other processes. PDX was rationally designed for efficient transport into tumor cells via the reduced folate carrier, or RFC-1, and effective intracellular drug retention. We believe these biochemical features, together with preclinical and clinical data in a variety of tumors, suggest that PDX may have a favorable potency and toxicity profile relative to methotrexate and certain other DHFR inhibitors.

About Peripheral T-cell Lymphoma

Peripheral T-cell lymphomas, or PTCLs, are a biologically diverse group of blood cancers that account for approximately 10% to 15% of all cases of non-Hodgkin's lymphoma (NHL), or about 6,700 patients. The average five year survival rate for PTCL patients is approximately 25%. There are currently no pharmaceutical agents approved for the treatment of either first-line or relapsed or refractory PTCLs.

About Allos Therapeutics, Inc.

Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company has two product candidates in late-stage clinical development: EFAPROXYN (efaproxiral), a radiation sensitizer currently under evaluation in a pivotal P
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
4. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
5. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
6. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
7. AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
10. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- ... Oxybutynin Hydrochloride Industry, 2009-2019 is a professional ... Chinese Oxybutynin Hydrochloride industry. The report firstly ... including its classification, application and manufacturing technology. ... top manufacturers of Oxybutynin Hydrochloride listing their ...
(Date:9/19/2014)... , September 19, 2014 ... ) has announced the addition of the ... report to their offering.      ... have been broadly classified into wide categories ... used for the treatment of different gynecological ...
(Date:9/19/2014)... 19, 2014 According to ... (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), ... technologies - Global Forecast to 2019" published by ... reach $19,786.3 Million by 2019 from $14,240.0 Million ... 2014 to 2019. Browse 74 market ...
Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
... Novavax, Inc.,(Nasdaq: NVAX ) announced today ... trial of its non-adjuvanted pandemic influenza virus-like,particle (VLP) ... Officer and Head of Clinical,Development stated, "The initial ... support further development of our pandemic influenza vaccine,through ...
... announce the,recent publication of important results from research into ... compounds, C75. The,Company is a leader in the research ... area of that research has been for the treatment,of ... is centered in the hypothalamus in the brain, research ...
Cached Medicine Technology:Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 2Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 3Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 4FASgen Announces New Discovery for Treatment of Stroke 2
(Date:9/19/2014)... York, NY (PRWEB) September 19, 2014 ... PR News at the Platinum PR and Top Places ... Hyatt in New York City. Camino received honorable mentions ... Shoestring Campaign” — for its work elevating Latina voices ... this incredible organization and be a part of its ...
(Date:9/19/2014)... Rockville Centre, NY (PRWEB) September 19, 2014 ... 17, the manufacturers of the embattled blood-thinner Xarelto, named ... County Court of Common Pleas, have moved the court ... the cases do not have sufficient connection with Philadelphia.* ... & Development, et al. (No. 140304328; Pa. Comm. Pls., ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- Although there is ... benefits, most middle-aged and older adults in the ... exercise, according to new research. Less than ... recommendations set by the Department of Health and ... is essential for promoting health and fitness and ...
(Date:9/19/2014)... a leading anti-ageing clinic has called its HGH Therapy ... has grown tremendously across USA in the last decade with ... It has far reaching benefits for ageing men and women ... and active lifestyle even beyond their middle age. , ... MetroMD said, “HGH or Human Growth hormones are the building ...
(Date:9/19/2014)... --- Domestic violence occurs at least as frequently, ... compared to opposite-sex couples, according to a review ... , Previous studies, when analyzed together, indicate that ... of lesbian, gay and bisexual individuals. However, a ... paints an incomplete picture of the true landscape, ...
Breaking Medicine News(10 mins):Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2Health News:Domestic violence likely more frequent for same-sex couples 2
... NEW ORLEANS, LA (November 15, 2010) � Following ... Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in ... (AAPS) Annual Meeting and Exposition, President Danny D. ... awards commemorating their contributions to the pharmaceutical sciences: ...
... HealthDay Reporter , MONDAY, Nov. 15 (HealthDay News) -- Although ... death rates in public places such as restaurants, malls and ... the risk of death when used in hospitals, a new ... the type of heart rhythms associated with the heart attack, ...
... is widely believed to be caused by the gradual accumulation in ... Amyloid beta peptide is formed from a protein known as APP, ... a key area of study for the disease does not ... published in the Journal of Biological Chemistry , show that ...
... By Amanda Gardner HealthDay Reporter , SUNDAY, Nov. ... St. Paul saw a sharp decline in the number of ... elsewhere in the United States, experts say. The decline ... choosing to smoke in the first place, according to research ...
... salt each day as a teenager could reduce high ... to research presented at the American Heart Association,s Scientific ... projected the nationwide health effects of a 3-gram reduction ... boys and girls. Teenagers eat more salt each day ...
... Nov. 14 (HealthDay News) -- New research suggests that vitamin ... patients, even though it appears to double the risk for ... given that prior research has revealed that blacks are overall ... experience a stroke, compared with white patients. Blacks also have ...
Cached Medicine News:Health News:AAPS presents awards to exemplary researchers 2Health News:AAPS presents awards to exemplary researchers 3Health News:AAPS presents awards to exemplary researchers 4Health News:External Defibrillators Not Much Help in Hospitals 2Health News:External Defibrillators Not Much Help in Hospitals 3Health News:'Magic number' 695 opens up new areas for Alzheimer's research 2Health News:Minneapolis Study Points to Sharp Drop in Smoking Rates 2Health News:Minneapolis Study Points to Sharp Drop in Smoking Rates 3Health News:Minneapolis Study Points to Sharp Drop in Smoking Rates 4Health News:Less salt in teenagers' diet may improve heart health in adulthood 2Health News:Vitamin D Shortage Not Tied to Stroke Deaths in Blacks: Study 2
Poppen-Gelpi Laminectomy Retractor, self-retaining....
Valin Hemilaminectomy Retractor, self retaining with rack and pinion action....
Scoville-Haverfield Hemilaminectomy Retractor...
Karlin Crank Frame Spinal Retractor Set is designed for posterior lumbar and thoracic spine surgery. Arm design allows the blades be pre-positioned in the wound prior to attachment....
Medicine Products: